Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIBRANT: Valproic Acid in Moderate to Severe Traumatic Brain Injury
NCT07166393Phase 3Not yet recruiting
- Sponsor
- Northwestern University
- Start
- May 2027
- Primary completion
- May 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of valproic acid in traumatic brain injury (TBI) (2 arms), sponsored by Northwestern University. Primary endpoint: Extended Glasgow Outcome Scale at 3 months. Planned start May 2027; status: not yet recruiting.
02
Drugs
valproic acid
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT07166393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07166393.